AB
DYN icon

Amalgamated Bank’s Dyne Therapeutics DYN Stock Holding History

Amalgamated Bank’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,889
Closed -$76K – 1972
2025
Q4 		$76K Buy
3,889
+1,087
+39% +$20.6K ﹤0.01% 1744
2025
Q3 		$35K Hold
2,802
– – ﹤0.01% 1946
2025
Q2 		$27K Hold
2,802
– – ﹤0.01% 2004
2025
Q1 		$29K Buy
2,802
+10
+0.4% +$143 ﹤0.01% 1942
2024
Q4 		$66K Hold
2,792
– – ﹤0.01% 1777
2024
Q3 		$100K Hold
2,792
– – ﹤0.01% 1714
2024
Q2 		$99K Buy
2,792
+796
+40% +$23.1K ﹤0.01% 1714
2024
Q1 		$57K Sell
1,996
-2,464
-55% -$55.7K ﹤0.01% 1833
2023
Q4 		$59K Buy
4,460
+161
+4% +$1.57K ﹤0.01% 2172
2023
Q3 		$39K Hold
4,299
– – ﹤0.01% 2353
2023
Q2 		$48K Buy
4,299
+1,091
+34% +$12.9K ﹤0.01% 2339
2023
Q1 		$37K Sell
3,208
-735
-19% -$9.55K ﹤0.01% 2422
2022
Q4 		$46K Hold
3,943
– – ﹤0.01% 2445
2022
Q3 		$50K Hold
3,943
– – ﹤0.01% 2460
2022
Q2 		$27K Buy
3,943
+312
+9% +$2.15K ﹤0.01% 2758
2022
Q1 		$35K Buy
+3,631
New +$30.9K ﹤0.01% 2620

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Amalgamated Bank's DYN Position: Q1 2026 in Review

Amalgamated Bank sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 3,889 shares — an estimated $76K sold.

Amalgamated Bank first reported a position in DYN in Q1 2022 and held it in 16 quarters. The position peaked at $100K in Q3 2024. 228 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Amalgamated Bank reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 3,889 Dyne Therapeutics shares in Q1 2026, an estimated $76K.
  • Amalgamated Bank first reported a position in Dyne Therapeutics in Q1 2022 and held it in 16 quarters.
  • Amalgamated Bank's Dyne Therapeutics position peaked at $100K in Q3 2024.
  • 228 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.